undamentalytics Newsletter
Sign in

Monte Rosa Therapeutics, Inc. revenue

Monte Rosa Therapeutics, Inc.'s revenue was $124m in fiscal 2025, up 63.5% on the year before. Over the last twelve months it was $28.7m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue07612429
Growth on the year before——+63.5%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Monte Rosa Therapeutics, Inc. $28.7m -83.9% —
Tonix Pharmaceuticals Holding Corp. $29.1m 196.0% —
Arcturus Therapeutics Holdings Inc. $29.4m -76.0% -51.9%
Stoke Therapeutics, Inc. $27.6m -86.2% 46.1%
Abeona Therapeutics Inc. $25.5m -87.7% 212.0%
Crispr Therapeutics AG $25.2m -34.3% -47.1%

Compare with peers

Head to head: GLUE vs TNXPARCT vs GLUEGLUE vs STOK

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Monte Rosa Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Monte Rosa Therapeutics, Inc.